MX2023014407A - Molécula de unión biespecífica que se une a vegf y ang2 y uso de la misma. - Google Patents

Molécula de unión biespecífica que se une a vegf y ang2 y uso de la misma.

Info

Publication number
MX2023014407A
MX2023014407A MX2023014407A MX2023014407A MX2023014407A MX 2023014407 A MX2023014407 A MX 2023014407A MX 2023014407 A MX2023014407 A MX 2023014407A MX 2023014407 A MX2023014407 A MX 2023014407A MX 2023014407 A MX2023014407 A MX 2023014407A
Authority
MX
Mexico
Prior art keywords
vegf
ang2
binding molecule
bispecific
antibody
Prior art date
Application number
MX2023014407A
Other languages
English (en)
Spanish (es)
Inventor
Yiming Li
Siyi Hu
Hua Jing
Original Assignee
Innovent Biologics Suzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innovent Biologics Suzhou Co Ltd filed Critical Innovent Biologics Suzhou Co Ltd
Publication of MX2023014407A publication Critical patent/MX2023014407A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2023014407A 2021-06-04 2022-06-02 Molécula de unión biespecífica que se une a vegf y ang2 y uso de la misma. MX2023014407A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110623779 2021-06-04
PCT/CN2022/096848 WO2022253314A1 (zh) 2021-06-04 2022-06-02 结合VEGF和Ang2的双特异性结合分子以及其用途

Publications (1)

Publication Number Publication Date
MX2023014407A true MX2023014407A (es) 2024-04-23

Family

ID=84323888

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023014407A MX2023014407A (es) 2021-06-04 2022-06-02 Molécula de unión biespecífica que se une a vegf y ang2 y uso de la misma.

Country Status (11)

Country Link
US (1) US20240247057A1 (cg-RX-API-DMAC7.html)
EP (1) EP4349861A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024520693A (cg-RX-API-DMAC7.html)
KR (1) KR20240023095A (cg-RX-API-DMAC7.html)
CN (1) CN117500828A (cg-RX-API-DMAC7.html)
AU (1) AU2022287100A1 (cg-RX-API-DMAC7.html)
CA (1) CA3221192A1 (cg-RX-API-DMAC7.html)
IL (1) IL309035A (cg-RX-API-DMAC7.html)
MX (1) MX2023014407A (cg-RX-API-DMAC7.html)
TW (1) TW202302633A (cg-RX-API-DMAC7.html)
WO (1) WO2022253314A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4400512A4 (en) * 2021-09-10 2025-07-23 Soter Biopharma Pte Ltd ANTI-ANG2 ANTIBODY, ITS PREPARATION METHOD AND ITS USE
AU2023404529A1 (en) * 2022-12-01 2025-07-10 Innovent Biologics (Suzhou) Co., Ltd. Preparation containing bispecific binding molecule binding to vegf and ang2 and use thereof
AU2025207813A1 (en) * 2024-01-12 2026-07-23 Novelty Nobility Inc. Bispecific antibody specifically binding to c-kit and vegf, and use thereof
TW202604956A (zh) * 2024-04-29 2026-02-01 大陸商深圳歐科健生物醫藥科技有限公司 Ang2/vegf 雙特異性結合分子
WO2026037351A1 (zh) * 2024-08-13 2026-02-19 长春金赛药业有限责任公司 同时结合vegf及ang-2的融合蛋白及其用途
CN121517578A (zh) * 2024-08-13 2026-02-13 长春金赛药业有限责任公司 同时结合VEGF及Ang-2的Fc融合蛋白及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
TWI426920B (zh) * 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗-vegf/抗-ang-2抗體
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
SI3495387T1 (sl) 2012-07-13 2021-12-31 Roche Glycart Ag Bispecifična protitelesa proti VEGF/proti ANG-2 in njihova uporaba pri zdravljenju bolezni očesnih žil
WO2016073157A1 (en) * 2014-11-06 2016-05-12 Genentech, Inc. Anti-ang2 antibodies and methods of use thereof
JP2017537896A (ja) * 2014-11-10 2017-12-21 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 二重特異性抗体及び眼科に使用する方法
EP3600442A1 (en) * 2017-03-22 2020-02-05 Genentech, Inc. Optimized antibody compositions for treatment of ocular disorders
US20220185875A1 (en) * 2019-03-18 2022-06-16 Jiangsu Hengrui Medicine Co., Ltd. Bispecific antibody specifically bound to vegf and ang2

Also Published As

Publication number Publication date
TW202302633A (zh) 2023-01-16
CN117500828A (zh) 2024-02-02
JP2024520693A (ja) 2024-05-24
EP4349861A4 (en) 2025-07-23
IL309035A (en) 2024-02-01
AU2022287100A1 (en) 2024-01-25
US20240247057A1 (en) 2024-07-25
KR20240023095A (ko) 2024-02-20
EP4349861A1 (en) 2024-04-10
WO2022253314A1 (zh) 2022-12-08
CA3221192A1 (en) 2022-12-08

Similar Documents

Publication Publication Date Title
DOP2024000207A (es) Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas
CL2022001670A1 (es) Inhibidores de proteínas kras mutantes
BR112021023457A2 (pt) Composto, uso do composto, composição, e, métodos para preparar a composição e um composto
CL2020001944A1 (es) Proteínas de fusión fc il-22 y métodos de uso.
CR20150625A (es) Composición que comprende anticuerpo que se fija al dominio ii de her2 y sus variantes acidas
CR20160206A (es) Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento C5
PE20181805A1 (es) Composiciones y anticuerpos anti-tim-3
BRPI1008145B8 (pt) Proteína de ligação de antígeno biespecífica, método para preparar uma proteína de ligação de antígeno biespecífica, micro-organismo transgênico, composição farmacêutica e uso da proteína de ligação de antígeno biespecífica
UY30511A1 (es) Agonistas de ep2
UY35854A (es) Métodos para la conjugación de oxima con polipéptidos ceto-modificados
DOP2022000035A (es) Composiciones que comprenden tigolaner para el control de parásitos
MX2021011976A (es) Composiciones de control de artropodos.
CR20170425A (es) Nuevas proteínas específicas para pioverdina y pioquelina
CL2023003694A1 (es) Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, métodos de uso
BR112017016636A2 (pt) formulação líquida estável para anticorpos monoclonais
CO6731074A2 (es) Composición vacunal para el control de las infestaciones por ectoparásitos
MX2020008125A (es) Composiciones que comprenden berberina.
MX2020006105A (es) Inmunógenos peptídicos de il-31 y formulaciones de estos para el tratamiento y/o la prevención de la dermatitis atópica.
AR117343A1 (es) AGENTES DE UNIÓN REVERSIBLE PARA ANTICUERPOS ANTI-FACTOR XI / XIa Y USOS DE LOS MISMOS
CL2023000491A1 (es) Composiciones de erenumab y usos de las mismas (divisional de solicitud n° 02519-2020).
AR106981A1 (es) Una composición antimicrobiana
MX2023001160A (es) Composicion farmaceutica del anticuerpo anti-pd-1 y uso del mismo.
CL2022001035A1 (es) Composiciones y métodos para minimizar la pérdida de proteínas a concentraciones de proteínas bajas
CL2025000292A1 (es) Anticuerpos tmem219 y usos terapéuticos de los mismos
CO2024000763A2 (es) Composiciones y métodos de los anticuerpos anti-pacap